{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:56:06Z","timestamp":1793811366913,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti\u2013PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable genomic aberrations. Patients stratified by PD-L1 tumor proportion score and smoking status were randomized 1:1, receiving \u226435 cycles 500\u2009mg dostarlimab or 200\u2009mg pembrolizumab, \u226435 cycles 500\u2009mg\/m<jats:sup>2<\/jats:sup> pemetrexed and \u22644 cycles cisplatin (75\u2009mg\/m<jats:sup>2<\/jats:sup>) or carboplatin (AUC 5\u2009mg\/ml\/min) Q3W. Primary endpoint was overall response rate (ORR) (blinded independent central review). Secondary endpoints include progression-free survival (PFS) based on investigator assessment, overall survival (OS) and safety. Exploratory endpoints include ORR by PD-L1 subgroup and duration of response. PERLA met its pre-specified endpoint. ORR (n\/N; 95% CI) is 45% (55\/121; 36.4\u201354.8) for DCT and 39% (48\/122; 30.6\u201348.6) for PCT (data cut-off: 07 July 23), numerically favoring dostarlimab in PD-L1-positive subgroups. Median PFS (months [95% CI]) is 8.8 (6.7\u201310.4) for DCT and 6.7 (4.9\u20137.1) for PCT (HR 0.70 [95% CI: 0.50\u20130.98]; data cut-off: 04 August 22). Median OS (months [95%\u00a0CI]) is 19.4 (14.5\u2013NR) for DCT and 15.9 (11.6\u201319.3) for PCT (HR 0.75 [95%\u00a0CI: 0.53\u20131.05]) (data cut-off: 07 July 23). Safety profiles are similar between groups. In this study, DCT shows similar efficacy to PCT and demonstrates clinical efficacy as first-line treatment for patients with metastatic non-squamous NSCLC.<\/jats:p>","DOI":"10.1038\/s41467-023-42900-4","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:01:46Z","timestamp":1699678906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-1593","authenticated-orcid":false,"given":"Sun Min","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-3371","authenticated-orcid":false,"given":"Ana Laura","family":"Ortega Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo dix Junqueira","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Sebasti\u00e1n","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Szijgyarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Huseinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Buss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Stjepanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"42900_CR1","unstructured":"GLOBOCAN. Lung cancer factsheet. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/15-Lung-fact-sheet.pdf (2020)."},{"key":"42900_CR2","unstructured":"American Cancer Society. Cancer Facts and Figures. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2022\/2022-cancer-facts-and-figures.pdf (2022)."},{"key":"42900_CR3","doi-asserted-by":"crossref","unstructured":"Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (update available at https:\/\/www.esmo.org\/content\/download\/347819\/6934778\/1\/ESMO-CPG-mNSCLC-15SEPT2020.pdf) (accessed November 2022). Ann. Oncol. 29 Suppl 4, iv192-iv237 (2018).","DOI":"10.1093\/annonc\/mdy275"},{"key":"42900_CR4","unstructured":"Cancer.net. Lung cancer non-small cell: statistics. https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics (2022)."},{"key":"42900_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"M Alexander","year":"2020","unstructured":"Alexander, M., Kim, S. Y. & Cheng, H. Update 2020: Management of Non-Small Cell\u00a0Lung Cancer. Lung 198, 897\u2013907 (2020).","journal-title":"Lung"},{"key":"42900_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","volume":"13","author":"R Chen","year":"2020","unstructured":"Chen, R. et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J. Hematol. Oncol. 13, 58 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"42900_CR7","doi-asserted-by":"publisher","first-page":"877594","DOI":"10.3389\/fonc.2022.877594","volume":"12","author":"SR Punekar","year":"2022","unstructured":"Punekar, S. R., Shum, E., Grello, C. M., Lau, S. C. & Velcheti, V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front. Oncol. 12, 877594 (2022).","journal-title":"Front. Oncol."},{"key":"42900_CR8","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S267433","volume":"14","author":"L Ai","year":"2020","unstructured":"Ai, L. et al. Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy. Drug. Des. Dev. Ther. 14, 3625\u20133649 (2020).","journal-title":"Drug. Des. Dev. Ther."},{"key":"42900_CR9","unstructured":"GlaxoSmithKline. JEMPERLI 500 mg concentrate for solution for infusion: Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jemperli-epar-product-information_en.pdf (2022)."},{"key":"42900_CR10","unstructured":"GlaxoSmithKline. JEMPERLI\u00ae (dostarlimab) US Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761174s006lbl.pdf (2023)."},{"key":"42900_CR11","doi-asserted-by":"publisher","first-page":"E415","DOI":"10.1016\/j.cllc.2022.05.013","volume":"23","author":"V Moreno","year":"2022","unstructured":"Moreno, V. et al. Safety and efficacy of dostarlimab in patients with recurrent\/advanced non-small cell lung cancer: results from cohort E of the phase I GARNET trial. Clin. Lung Cancer 23, E415\u2013E427 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"42900_CR12","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"42900_CR13","unstructured":"ClinicalTrials.gov. Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer. https:\/\/clinicaltrials.gov\/study\/NCT04252365 (2020)."},{"key":"42900_CR14","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1200\/JCO.2022.40.16_suppl.9032","volume":"40","author":"S-YM Liu","year":"2022","unstructured":"Liu, S.-Y. M. et al. Abstract 9032: Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non\u2013small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901). J. Clin. Oncol. 40, 9032\u20139032 (2022).","journal-title":"J. Clin. Oncol."},{"key":"42900_CR15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel, S. et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non\u2013Small-Cell Lung Cancer. J. Clin. Oncol. 38, 1505\u20131517 (2020).","journal-title":"J. Clin. Oncol."},{"key":"42900_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"42900_CR17","doi-asserted-by":"crossref","unstructured":"Peters, S. et al. Poster 107P: Outcomes of patients with metastatic non-small-cell lung cancer receiving first-line immunotherapy with or without chemotherapy: real-world evidence versus clinical trial results (CORRELATE). In: European Society for Medical Oncology Immuno-Oncology Congress 2022 (2022).","DOI":"10.1016\/j.iotech.2022.100211"},{"key":"42900_CR18","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"key":"42900_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2020","unstructured":"Nishio, M. et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J. Thorac. Oncol. 16, 653\u2013664 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"42900_CR20","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili, M. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat. Med. 28, 2374\u20132380 (2022).","journal-title":"Nat. Med."},{"key":"42900_CR21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2022","unstructured":"Johnson, M. L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study. J. Clin. Oncol. 41, 1213\u20131227 (2022).","journal-title":"J. Clin. Oncol."},{"key":"42900_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/ijc.31136","volume":"142","author":"F Passiglia","year":"2018","unstructured":"Passiglia, F. et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int. J. Cancer 142, 1277\u20131284 (2018).","journal-title":"Int. J. Cancer"},{"key":"42900_CR23","doi-asserted-by":"publisher","first-page":"102812","DOI":"10.1016\/j.critrevonc.2019.09.004","volume":"144","author":"E Rofi","year":"2019","unstructured":"Rofi, E. et al. Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Crit. Rev. Oncol. Hematol. 144, 102812 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"42900_CR24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association.","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"42900_CR25","unstructured":"ClinicalTrials.gov. Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189\/KEYNOTE-189). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02578680 (2015)."},{"key":"42900_CR26","doi-asserted-by":"crossref","unstructured":"Granados, A. L. O. et al. Dostarlimab or Pembrolizumab + Chemotherapy in Previously Untreated Metastatic Non Squamous Non-Small Cell Lung Cancer: Patient and Disease Characteristics Subgroup Analyses From the PERLA Trial (Poster #44P). In: European Lung Cancer Congress (2023).","DOI":"10.1016\/S1556-0864(23)00298-8"},{"key":"42900_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 17, 343\u2013346 (1996).","journal-title":"Control. Clin. Trials"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42900-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:02:39Z","timestamp":1699678959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42900-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42900"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-42900-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M.L. has received research grants from Yuhan and Janssen; received consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, Takeda, Guardant and J Ints Bio; and received research grants from AstraZeneca, Beigene, Boehringer Ingelheim, GSK, Roche, Hengrui, BridgeBio Therapeutics, Oscotec, and Daichii-Sankyo. S.P. has an advisory role with AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Peerview, Pfizer, PRIME, Regeneron, RMEI, Roche\/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, and Vaccibody; has been an invited speaker for AiCME, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Foundation Medicine, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Mirati, Novartis, PER, Peerview, Pfizer, Prime, Roche\/Genentech, RTP, Sanofi, and Takeda; and received research grants from Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, and Roche\/Genentech. A.L.O.G. is an employee of the Servicio Andaluz de Salud and has had an advisory role for Roche, Bristol Myers Squibb, and Merck Sharp Dohme. GdJP has no conflicts of interest to disclose. C.S.F. has been an invited speaker for Fundacion Respirar. G.L.R. has received consulting fees from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, Amgen, Sanofi, Italfarmaco and Pfizer; received honoraria from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, Amgen, and Sanofi; received travel grants from Roche, BMS, and MSD; had an advisory role for Roche, Novartis, BMS, MSD, AstraZeneca, and Sanofi; and been an investigator for clinical trials sponsored by Roche, Novartis, BMS, MSD, AstraZeneca, GSK, Amgen, and Sanofi. MS has had contracts for clinical trial activities (institutional and personal as site Principal Investigator) with GSK, Merck Serono, BMS, MSD, Roche, Sanofi, Regeneron, Astellas, Amgen, Bayer, BeiGene, Clovis, Tesaro, Gilead, Bioven, Novartis, Pfizer, Eli Lilly, Pharma Mar, AbbVie, Astra Zeneca, Mylan, and Daiichi Sankyo. JSA has been an invited speaker for Kyowa Kirin, Amgen Korea, Yuhan, AstraZeneca Korea, Menarini Korea, Bayer Korea, Takeda Phar, Novartis Korea, Hanmi, BC World, Pfizer, Roche Korea, and Boehringer Ingelheim; and had an advisory role for Yuhan, Bayer Korea, Yooyoung, Pharmbio Korea, Vifor Pharma, and Bixink. MR has had an advisory role for Amgen, AstraZeneca, Beigene, BMS, Boehringer Ingelheim, Daiichi-Sankyo, GSK, Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, Samsun Bioepsis, and Sanofi. Z.S. is an employee of GSK. N.H. is a former employee of GSK (at time of study) and is a current employee of Lantheus Medical Imaging. E.Z. is an employee of GSK. E.B. is an employee of GSK and holds stocks\/shares in GSK. N.S. is an employee of GSK and their spouse works for Debiopharm. S.O\u2019.D. is an employee of GSK and their spouse works as a federal employee. F.d.M. has had an advisory role for AstraZeneca, Roche, Novartis, Merck, BMS, and MSD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7301"}}